Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimul⦠read more
Healthcare
Biotechnology
23 years
USD
Exclusive to Premium users
$3.95
Price+2.47%
$0.10
$125.704m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$101.706m
-
1y CAGR-
3y CAGR-
5y CAGR-$165.520m
-
1y CAGR-
3y CAGR-
5y CAGR-$7.15
-
1y CAGR-
3y CAGR-
5y CAGR-$336.308m
$185.221m
Assets$521.529m
Liabilities$402.757m
Debt217.5%
-5.2x
Debt to EBITDA-$127.362m
-
1y CAGR-
3y CAGR-
5y CAGR